As Robert F. Kennedy Jr. settles into his role as President Donald Trump’s health secretary, one major promise he’s made is ...

Kneat's SaaS model automates validation processes in pharma and biotech, reducing errors and ensuring compliance. Learn why ...

Violations highlight growing concerns over the unchecked rise in medicine prices and their impact on affordability ...

Samsung Biologics, Celltrion Lead Pharmaceutical Industry with Average Salary Over 100 Million Won Biopharmaceutical giants ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

Soliman said consumers could see price increases or shortages of generic drugs in the country. There are some laws that ...

Merck and Bristol-Myers Squibb are key players in cancer treatment. Find out why MRK and BMY stocks have different prospects ...

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the drug development inputs & services stocks, ...

Somehow Washington regards the industry, which has saved and improved tens of millions of lives, as a villain.

Using detailed financial reports from thousands of firms, the researchers found that in 2018, U.S. multinationals shifted about $20-25 billion to tax havens — far lower than prior estimates of about ...